A Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), in Subjects With Non-ST-Elevation Acute Coronary Syndromes - ANTHEM (Anticoagulation With rNAPc2 to Help Eliminate MACE)/TIMI 32. Amendment 3 - A Single Arm, Open-Label Study of rNAPc2 With Reduced Doses of Unfractionated Heparin.

Trial Profile

A Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), in Subjects With Non-ST-Elevation Acute Coronary Syndromes - ANTHEM (Anticoagulation With rNAPc2 to Help Eliminate MACE)/TIMI 32. Amendment 3 - A Single Arm, Open-Label Study of rNAPc2 With Reduced Doses of Unfractionated Heparin.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2009

At a glance

  • Drugs NAPc2 (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms ANTHEM-TIMI-32
  • Most Recent Events

    • 05 May 2009 Lead trial centres, investigator (Deitcher S) added as reported by ClinicalTrials.gov.
    • 05 May 2009 ARCA Biopharma added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 17 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top